Nail disorders in a woman treated with ixabepilone for metastatic breast cancer.
Ixabepilone (Ix) (BMS-247550) is a potent member of a new class of microtubule-stabilizing cytotoxic agents known as epothilones. In pre-clinical studies, Ix has shown anticancer activity against several cancer types, including paclitaxel-resistant models, both in vitro and in vivo. The major toxicities associated with Ix are myelosuppression, sensory neuropathy and neutropenia. Other minor side-effects include asthenia/fatigue, stomatitis, anorexia, alopecia, skin reaction, hypersensitivity reactions and a fluid-retention syndrome. Although Ix is functionally correlated to taxanes, no previous evidence exists regarding Ix-related nail disorders. Here, we report a case of a 59-year-old woman treated with Ix at 40 mg/m2 day 1 q 21 days who, after 8 cycles of therapy, developed onycholysis and subungual hemorrhagic bullas in the fingernails.
Alimonti
Andrea
A
Division of Medical Oncology A, Regina Elena Cancer Institute, Rome, Italy. alimonta@mskcc.org
Nardoni
Chiara
C
Papaldo
Paola
P
Ferretti
Gianluigi
G
Caleno
Maria Pia
MP
Carlini
Paolo
P
Fabi
Alessandra
A
Rasio
Debora
D
Vecchione
Aldo
A
Cognetti
Francesco
F
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D034261:Epothilones / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009260:Nail Diseases / Q000139:chemically induced*
D000970:Antineoplastic Agents; D034261:Epothilones; C430592:ixabepilone